Education
About Us
Working with TipRanks
Follow Us
GeNeuro SA (FR:GNRO)
:GNRO
GNRO Stock Chart & Stats
€0.03
€0.00(0.00%)
―
--
Day’s Range― - ―
52-Week Range€0.02 - €0.12
Previous CloseN/A
VolumeN/A
Average Volume (3M)19.14K
Market Cap
€914.44K
Enterprise ValueN/A
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta1.49
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding29,760,933
10 Day Avg. Volume0
30 Day Avg. Volume19,139
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.75
Revenue Forecast (FY)N/A
GNRO FAQ
What was GeNeuro SA’s price range in the past 12 months?
GeNeuro SA lowest stock price was €0.02 and its highest was €0.12 in the past 12 months.
What is GeNeuro SA’s market cap?
GeNeuro SA’s market cap is €914.44K.
When is GeNeuro SA’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were GeNeuro SA’s earnings last quarter?
Currently, no data Available
Is GeNeuro SA overvalued?
According to Wall Street analysts GeNeuro SA’s price is currently Undervalued.
Does GeNeuro SA pay dividends?
GeNeuro SA does not currently pay dividends.
What is GeNeuro SA’s EPS estimate?
GeNeuro SA’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does GeNeuro SA have?
GeNeuro SA has 29,760,933 shares outstanding.
What happened to GeNeuro SA’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of GeNeuro SA?
Currently, no hedge funds are holding shares in FR:GNRO
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
GeNeuro SA
GeNeuro SA, a clinical-stage biopharmaceutical company, develops drugs for the treatment of neurodegenerative and autoimmune diseases. The company's lead therapeutic candidate is temelimab, a monoclonal antibody, which has completed Phase IIb clinical trial for multiple sclerosis; and is in Phase IIa to treat type 1 diabetes, as well as is in Phase I for the treatment of chronic inflammatory demyelinating polyneuropathy. It has cooperative research and development agreements with The National Institute of Neurological Disorders and Stroke to develop novel therapeutic antibodies for the treatment of amyotrophic lateral sclerosis; and Academic labs to develop inflammatory psychosis, as well as a research collaboration agreement with International Center for Infectiology Research; and with Northwestern University for human endogenous retrovirus W envelope protein (HERV-W ENV) in long-haul COVID patients. The company was incorporated in 2006 and is headquartered in Plan-les-Ouates, Switzerland.